Christine McMahon on Muck Rack

Christine McMahon

Milwaukee
As seen in: Nature, Sydney Morning Herald, The Age, Wicklow People, Brisbane Times, WAtoday, Cancer Discovery, BizTimes Milwaukee, European Journal of Obstetrics & Gynaecology and Reproductive Biology, Points in Case and
Trainer, consultant & keynote speaker Workshops: Sales Plasticity Negotiating Persuasive Presentations Leadership Plasticity
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christine

Contact Christine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

|
By Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Tulika Gupta, Jessica M. Stempel, Najla Al Ali, Amy E. DeZern, Mikkael Sekeres, Geoffrey L Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Michael Savona, Constantine N Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice Wang, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David A Sallman, Anoop K. Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, María Díez-Campelo, David Valcárcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Rami S. Komrokji, Amer M Zeidan, Hayley Hawkins, Namrata Sonia Chandhok, Ted M. Getz, Amyah C. Harris, Jaclynn Campos
| Nature Verified
Abstract Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated.
Open in Who Shared Issue with article?

Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis - Leukemia

|
By Chelsea Harris, Jennifer Knapp, Christine McMahon
| Nature Verified
Abstract Myelodysplastic neoplasm (MDS) is a hematopoietic stem cell disorder that may evolve into acute myeloid leukemia. Fatal infection is among the most common cause of death in MDS patients, likely due to myeloid cell cytopenia and dysfunction in these patients. Mutations in genes that encode components of the spliceosome represent the most common class of somatically acquired mutations in MDS patients.
Open in Who Shared Issue with article?

A Typical Work Day or a King Dying Slowly on a TV Show?

|
By Christine McMahon
| Points in Case
Those in attendance pretend to hang on the leader’s every word More than one attendee wants the leader’s job The leader conveys a mixture of work-related information and random memories from his youth Women are underrepresented The news is not good It seems to take days or even weeks, but it’s usually less than an hour in real-time The pain is unbearable Someone is feeding the leader false information and unduly influencing him Christopher Lee is there Someone rambles on about their children...
Open in Who Shared Issue with article?
See all 27 licensed articles (32 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified